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AT A GLANCE COMMENTARY:  
Scientific Knowledge on the subject: Failure of tissue repair leads to fibrosis and organ 
dysfunction and is an increasing cause of disease. Idiopathic pulmonary fibrosis (IPF) is an 
exemplar of this process in which Vascular Endothelial Growth Factor-A (VEGF-A) has been 
pathogenically implicated. 
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What this study adds to the field: We show that IPF is associated with an increased expression 
of an inhibitory VEGF-A splice variant (VEGF-A165b) in IPF lung tissue, isolated IPF lung 
fibroblasts and plasma of IPF patients with progressive disease. In a mouse model of pulmonary 
fibrosis alveolar type II cell (ATII) specific deficiency of VEGF-A or constitutive over-
expression of VEGF-A165b inhibited the development of pulmonary fibrosis, as did treatment 
with intra-peritoneal delivery of VEGF-A165b to wild-type mice. These results indicate that 
changes in the bioavailability of VEGF-A sourced from ATII cells, namely the ratio of VEGF-
Axxxa to VEGF-Axxxb, are critical in the development of pulmonary fibrosis and may be a 
paradigm for the regulation of tissue repair.
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ABSTRACT:  
 
Rationale: Fibrosis following lung injury is related to poor outcome and Idiopathic Pulmonary 
Fibrosis (IPF) can be regarded as an exemplar. Vascular Endothelial Growth Factor-A (VEGF–
A) has been implicated in this context but there are conflicting reports as to whether it is a 
contributory or protective factor. Differential splicing of the VEGF-A gene produces multiple 
functional isoforms including VEGF-A165a, and VEGF-A165b a member of the inhibitory family. 
To-date there is no clear information on the role of VEGF in IPF. 
Objectives: To establish VEGF isoform expression and functional effects in IPF. 
Methods: We used tissue sections, plasma and lung fibroblasts from IPF patients and controls. 
In a bleomycin-induced lung fibrosis model we used wild type MMTV mice and a triple 
transgenic mouse SPC-rtTA
+/-
TetoCre
+/-
LoxP-VEGF-A
+/+ 
to conditionally induce VEGF-A 
isoform deletion specifically in the ATII cells of adult mice.  
Measurements and main Results: IPF and normal lung fibroblasts differentially expressed and 
responded to VEGF-A165a and VEGF-A165b, in terms of proliferation and matrix expression.  
Increased VEGF-A165b was detected in sera of progressing IPF patients.  In a mouse model of 
pulmonary fibrosis alveolar type II cell (ATII) specific deficiency of VEGF-A or constitutive 
over-expression of VEGF-A165b inhibited the development of pulmonary fibrosis, as did 
treatment with intra-peritoneal delivery of VEGF-A165b to wild-type mice. 
Conclusions: These results indicate that changes in the bioavailability of VEGF-A sourced from 
ATII cells, namely the ratio of VEGF-Axxxa to VEGF-Axxxb, are critical in development of 
pulmonary fibrosis and may be a paradigm for the regulation of tissue repair.  
Word Count: 250 Keywords: Idiopathic pulmonary fibrosis, Vascular endothelial Growth 
Factor (VEGF), animal models of pulmonary fibrosis 
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Introduction 
 
Fibrosis in the lung or elsewhere is part of the normal repair mechanism following injury. 
Idiopathic pulmonary fibrosis (IPF) can be considered as a paradigm of an aberrant repair 
process in response to repeated and unidentified injury. IPF is a devastating progressive fibrosing 
lung disease of unknown cause that is increasing in incidence(1). Median survival is 3-5 years 
and treatment options are limited(2, 3), leading to an estimated mortality rate of more than 50 
deaths per 1,000,000 persons in the US(4) and UK(1) . 
Vascular Endothelial Growth Factor-A, originally described as an angiogenic factor, belongs to a 
super-family of glycoproteins, and signals through tyrosine kinase receptors VEGF receptor 1 
(VEGFR1) and VEGF receptor 2 (VEGFR2) and co-receptors, neuropilins 1 and 2 (NP1 and 
NP2)(5, 6). However, VEGF biology has undergone radical revision since its discovery. It has 
been identified in primitive organisms that have no vasculature(7), is not specific to endothelial 
cells and is increasingly recognized as vital in the function and maintenance of non-endothelial 
cells(8, 9). In vitro studies have confirmed that VEGF-A is abundant in lung tissue, especially in 
alveolar epithelium(10-14) and has a role in lung development(15) and maturation(16). In the 
healthy lung processes classically associated with VEGF-A are extremely restricted(14, 17, 18). 
This apparent paradox has led to controversy about the role of VEGF-A in the normal and 
diseased lung(19).  
Several pathogenic mechanisms for the development of IPF have been proposed but currently a 
form of recurrent alveolar type II (AT II) epithelial injury leading to aberrant collagen deposition 
from fibroblasts is most widely accepted(20). Evidence on the role of VEGF-A in IPF 
conflicts(21),(22),(23). Evidence that VEGF-A may facilitate fibrogenesis comes from the 
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extensive trials of FDA approved nintedanib, a triple tyrosine kinase inhibitor, including the 
VEGFR2 receptor(24, 25). In contrast, several clinical studies have indicated a reparative role for 
VEGF-A in the lung (17, 18), with pre-clinical studies suggesting a protective role for VEGF-A 
against the development of excessive pulmonary fibrosis as a result of lung injury(26-28).  
Differential splicing of the VEGF-A gene produces multiple functional isoforms (29) : proximal 
splice site selection with exon 8 produces the conventional family of VEGF-Axxxa isoforms. 
Distal splice site selection within exon 8 produces an alternative family of isoforms (VEGF-
Axxxb family), that have the same number of amino acids as the conventional family in humans, 
but six different amino acids at the C terminus(30). The most widely studied of these isoforms, 
VEGF-A165b, is functionally different from VEGF-A165a(30, 31). VEGF-A165b inhibits canonical 
VEGF-A signalling by competitive interference with conventional isoforms at the VEGFR2–
NP1 receptor complex, preventing full downstream signalling by VEGFR2(32). Knowledge of 
inhibitory VEGF-A variants in clinical tissue repair syndromes is limited(33). We have shown 
that they inhibit VEGF-A165a induced ATII and pulmonary microvascular proliferation in 
vitro(10). Functional Murine VEGF-A165b has been described (33). Thus a number of regulatory 
events at the 3′ end of the VEGF-A gene are required for precise physiological control of VEGF-
A bioavailability(34). 
Hitherto, the vast majority of studies have examined VEGF as a single molecule. Differential 
expression of the numerous VEGF-A isoforms offers one explanation for the apparent 
discrepancies observed in the literature. In this study we have focused on the role of VEGF in 
relation to fibroblast function.  We show that ATII cell-specific production of VEGF-A is a key 
checkpoint for controlling lung fibrogenesis. VEGF-A165b acts as a natural regulator of this 
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process and has potential therapeutic applications for restoring homeostasis to the lung and 
treating fibrosis. Some of the results have been previously reported in abstract form(35-37). 
 
Methods: 
Human tissue collection  
Anonymised human lung biopsies and bronchoalveolar lavage (BAL) were donated from 
patients undergoing clinically indicated procedures. The Bristol institutional review boards 
granted ethical approval. Additional IPF tissue and plasma samples came from the Lung Tissue 
Research Consortium (LTRC), USA, and Toby Maher (Royal Brompton Hospital, UK, (38)).  
Primary lung fibroblast culture 
Primary lung fibroblasts were explanted from lung biopsies as previously described or obtained 
from the American Type Culture Collection.  
RT-PCR and Quantitative RT-PCR  
Total RNA was extracted using the Quick RNA
TM
 kit (Zymo Research) and reverse transcribed 
with Taqman High Capacity RNA-to-cDNA kit (Applied Biosystems). Individual qRT-PCR 
reaction mixes were made using manufacturer recommendations (2x SensiFAST SYBR Hi-ROX 
(Bioline). Human and murine primer sets are in Tables E1 and E2. Expression of human VEGF-
Axxxa and VEGF-Axxxb isoforms were also quantified (39).  
Cell Immunofluorescence 
Cells were fixed, permeabilised and blocked before incubation with primary antibody overnight 
and then secondary antibody before image capture. 
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Western-Blot Analysis 
Cell lysates were prepared using radioimmunoprecipitation buffer (Sigma,), containing protease 
and phosphatase inhibitor cocktails (Sigma). Lysates were fractionated, immunoblotted, blocked, 
then incubated with primary antibodies and loading controls. High Performance Liquid 
Chromatography (HPLC)  
HPLC was used to quantify fibroblast collagen production (40). 
Immunohistochemistry 
Slides were de-waxed before rehydration and antigen retrieval. Endogenous peroxidases were 
blocked and sections incubated with primary antibody or IgG control.  
ELISA of PanVEGF-A and VEGF-A165b 
PanVEGF-A and VEGF-A165b levels were quantified using PanVEGF-A and VEGF-A165b 
ELISA sets (R&D systems). 
Cell Proliferation assay and wound healing –migration Assay 
Fibroblasts were seeded into 24-well plates or IBIDI culture chambers, quiesced and following 
stimulation, counted or imaged.   
Animal housing and breeding 
All experiments were carried out in accordance with the UK Animals (Scientific Procedures) Act 
1986 and University of Bristol ethical review panel approval. TG mice constitutively over-
expressing VEGF-A165b (MMTV-VEGF165b
+/-
) were generated as previously described(41). 
SPC-rtTA
+/-
Tet-O-Cre
+/-
LoxP VEGF
+/+ 
mice were generated on C57Bl6 background by crossing 
three transgenic mouse lines: LoxP-VEGF (Genentech, San Franscisco, USA(42), Cre-
recombinase, under control of a tetracycline-responsive promoter element (Tet-O) and TG mice 
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expressing the reverse tetracycline-controlled transactivator (rtTA) protein under control 
surfactant, pulmonary-associated protein C, promoter(SPC)(Jackson)(43).  
Animal studies 
The Bleomycin-induced model of pulmonary fibrosis was used (44). Lung fibrosis was assessed 
by fibronectin and pro-collagen-1α mRNA expression and histologically by Masson’s Trichrome 
staining and lung fibrosis score.  
Further experimental details are available on line.  
 
Statistical analysis 
Statistical analysis was performed using Graph Pad Prism software (Version 5.0). Unpaired t-test 
was used, with or without Welch’s correction dependent on the variance of data. ANOVA with 
post-hoc Holm’s Sidak multiple comparisons analysis was used for multiple comparisons. For all 
tests a p < 0.05 was considered statistically significant.  
 
Results   
PanVEGF-A and VEGF-Axxxb expression in IPF patients 
Whole lung tissue expression of panVEGF-A (collective VEGF- A isoforms), VEGF-Axxxb, 
VEGF-A121a, VEGF-A165a and VEGF-A189a was detected at mRNA level (Figure 1a), confirmed 
by sequencing (Figure E 1) and quantified (Figure 1b). PanVEGF-A protein levels in whole 
lung were comparable between normal and IPF, but intriguingly VEGF-A165b protein expression 
was dramatically increased in IPF lung tissue (Figure 1c).  VEGF-A165b, but not panVEGF-A in 
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baseline plasma samples of subsequent progressors (death or >10% decline in FVC at 12 
months) were significantly greater than non-progressors (Figure 1d).  
Levels of VEGF-A (representing only the soluble isoforms, VEGF-A121 and VEGF-A165), 
investigated by pan-VEGF-A ELISA, were significantly lower in bronchoalveolar lavage fluid 
(BALF) of IPF patients compared to controls (Figure 1e), as previously reported (13, 45-47). 
Patient demographics were comparable (Figure E 2a). VEGF-A165b was undetectable in BALF, 
using an ELISA specific for an epitope encoded by exon 8b suggesting it was not secreted into 
an area accessible by this procedure or was below the detection limit (10pg/ml). Using 
immunohistochemistry, we found that in both normal and IPF lung panVEGF-A and VEGF-
A165b were prominent within alveolar epithelium (AEC) (Figure 1f and Figure E2b) but also 
localised to macrophages, lymphocytes and fibroblasts, particularly outside the fibrotic focus. 
These data suggest that there is an increased expression of VEGF-A165b in IPF, one source being 
ATII cells as previously shown in normal lung(10). To understand the biological potential of 
these findings in IPF we investigated the expression of the receptors and co-receptors necessary 
for functional activity. 
 
VEGF receptor and co-receptors in IPF patients  
Expression of VEGFR1, VEGFR2, NP1 and NP2 was detected at the mRNA level in normal and 
IPF lung whole lung tissue (Figure 2a).  Expression of VEGFR1 and NP1 was significantly up-
regulated in IPF lung.  
Using immunohistochemistry, we found that in normal and IPF lung VEGFR1, VEGFR2, NP1 
and NP2 were expressed on AEC, macrophages, lymphocytes and fibroblasts surrounding 
fibrotic foci with reduced expression within the foci (Figure 2b and Figure E 3A).  
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Lung whole tissue lysates expressed VEGFR1, VEGFR2, NP1 and NP2 protein (Figure 2c). 
There was a significant reduction in protein expression of VEGFR1 in the whole IPF lung 
samples (fibrotic foci and surrounding tissue) with a trend to reduced VEGFR2 and NP1. Co-
staining of VEGFR1 and VEGFR2 with epithelial-specific E-Cadherin suggests that non-
endothelial cells are VEGF-A targets (Figure E 3B).  
These data demonstrated the potential for VEGF-A to have functional effects in fibrotic lung. In 
this context, we then looked at isolated fibroblast cultures, the potential effector cells, from IPF 
and normal subjects. 
 
VEGF-A receptors and co-receptors are expressed by primary lung fibroblasts and VEGF-
A stimulation stimulates downstream signaling pathways  
VEGFR1, VEGFR2, NP1 and NP2 were endogenously expressed by fibroblasts from normal 
subjects (NF) and IPF patients (FF), at the mRNA level (Figure E 3C). FF expressed less 
VEGFR1 and NP2 protein (Figure 3a). Surprisingly, these cells did not express mature 
VEGFR2 protein by western blotting. These results were corroborated by ELISA; the expression 
of VEGFR2 was below the detection limit (≤30pg/ml). VEGFR2 is conventionally considered 
the main signalling receptor so we investigated whether signalling could occur. Treatment of NF 
and FF cultures with rhVEGF-A165a or rhVEGF-A165b proteins led to increased phosphorylation 
of MEK1/2 (Mitogen/Extracellular signal related Kinase) and p42/44 MAPK (Mitogen Activated 
Protein Kinase) proteins (Figure 3b and Figure E 4). 
 
 
 
Page 10 of 59 AJRCCM Articles in Press. Published on 29-June-2017 as 10.1164/rccm.201603-0568OC 
 Copyright © 2017 by the American Thoracic Society 
 11 
 
VEGF-A isoforms are expressed in primary lung fibroblasts  
NF and FF were characterized as expressing three major VEGF-A isoforms detectable at the 
RNA level by RT-PCR and confirmed by sequencing (Figure E 5 and E 6). Comparable levels 
of panVEGF-A and VEGF-Axxxb mRNA were demonstrated in NF and FF by qRT-PCR (Figure 
E 7). 
In contrast, comparable protein expression of panVEGF-A, but increased expression of VEGF-
Axxxb isoforms in FF cell lysates was identified by western blotting (Fig 3c). Quantification of 
panVEGF-A and VEGF-Axxxb protein expression in cell lysates of NF and FF cultures by ELISA 
supported these findings (Figure 3d).  
Localisation of panVEGF-A and VEGF-A165b expression by immunofluorescence demonstrated 
cytoplasmic localisation in all NF and FF, with additional panVEGF-A perinuclear staining 
(Figure 3e and Figure E 8). These data suggest an additional potential for autocrine effects of 
panVEGF-A and VEGF-A165b on fibroblasts. 
Having shown the potential for functional effects of VEGF-A165a and VEGF-A165b on fibroblasts 
we then explored how they might relate to IPF pathology. 
 
VEGF-A165a and VEGF-A165b recombinant proteins have differential effects on fibroblast 
proliferation, migration and ECM expression 
We examined fibroblastic fibronectin and collagen expression (Figure 4a-c). Administration of 
rhVEGF-A165a significantly increased protein expression of fibronectin but not collagen by NF 
and FF.  No significant effect was observed for either protein following rhVEGF-A165b 
administration (Fig. 4a,c). However, with increasing levels of VEGF-A165b, the VEGF-A165a-
induced increase in fibronectin was inhibited, an effect more apparent for FF (Figure 4b).  In the 
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presence of both isoforms, VEGF-A165b inhibited collagen production in NF but not FF (Figure 
4c).  
Recombinant VEGF-A165a also significantly increased the proliferation of FF, inhibited by the 
concomitant addition of VEGF-A165b (Figure 4d). Concomitant treatment of NF with VEGF-
A165a and VEGF-A165b inhibited cell proliferation compared to VEGF-A165a alone. 
Furthermore, VEGF-A
165
a and VEGF-A
165
b significantly increased NF migration. This effect 
was blocked by the concomitant treatment of VEGF-A
165
a and VEGF-A
165
b. In contrast, 
recombinant VEGF-A proteins had no significant effect on FF migration (Figure 4e and Figure 
E 9). 
Collectively these data supported an in-vitro mechanism by which VEGF-A165a could induce a 
fibrotic response ameliorated by VEGF-A165b. In the context of IPF, VEGF-A165b could 
ameliorate the development of IPF with ATII cells as the predominant source and fibroblasts as 
the likely effector cells, so to consider this in more detail we turned to an animal model. 
Alveolar epithelial expression of VEGF-Axxxa is essential for development of pulmonary 
fibrosis. 
To determine the effect of VEGF-A on the development of Bleomycin (BLM)-induced 
pulmonary fibrosis(44), we generated a triple transgenic mouse SPC-rtTA
+/-
TetoCre
+/-
LoxP-
VEGF-A
+/+ 
(termed STCLL) on a
 
C57Bl/6 background to conditionally induce the deletion of 
VEGF-A isoforms specifically in the ATII cells of adult mice. Tissue specificity of Cre-
recombinase activity following doxycycline induction was confirmed by in-vivo imaging of 
doxycycline induced GFP-SPC-rtTA
+/-
TetoCre
+/-
LoxP-VEGF-A
+/- 
mice
 
(termed GFP-STCL) 
(Figure 5a and Figure E 10). Quantitative RT-PCR of whole lung tissue RNA extracts 
demonstrated reduced panVEGF-A in doxycycline induced TG mice. In situ hybridisation, 
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indicated a lack of VEGF-A mRNA in the murine ATII cells and panVEGF-A 
immunohistochemistry corroborated findings of reduced ATII-derived VEGF-A (Figure 5a).  
Deletion of ATII VEGF-A, significantly reduced the development of BLM-induced pulmonary 
fibrosis by both a blindly assessed lung fibrosis score and reduced collagen deposition and 
architectural distortion (Figure 5b). Furthermore, lung fibronectin mRNA expression was 
significantly reduced in BLM-treated STCLL mice compared to BLM-treated WT controls, with 
a trend towards a reduction in pro-collagen-1α mRNA levels in these TG mice (Figure 5b).  This 
demonstrates that ATII expression of VEGF-A is required for fibrosis to occur. 
VEGF-A165b may be protective against the formation of pulmonary fibrosis 
A TG mouse that over-expresses VEGF-A165b using a MMTV promoter as a driver of expression 
has been described(41). This mouse has increased levels of the MMTV-VEGF-A165b transgene 
and human VEGF-A165b in the lung (Figure E 11a). H&E stained lung sections of TG mice 
were histologically normal, in particular with no vascular abnormalities, as might be expected in 
view of the established compartmentalization of lung VEGF(14) (Figure E 11b). IHC staining of 
TG mouse lung sections demonstrated increased VEGF-A165b expression localized to alveolar 
epithelial cells, compared to both mouse IgG and WT controls (Figure 6a). Homogenized lung 
tissue extracts from MMTV-VEGF-A165b mice expressed significantly more VEGF-A165b 
protein than littermate WT controls by ELISA, with detectable VEGF-A165b levels in BALF of 
TG mice, but below the detection limit of the ELISA in WT controls (Figure 6a).  
In this pre-clinical model the development of pulmonary fibrosis was significantly reduced in TG 
mice compared to WT mice (Figure 6b). Pro-collagen-1α mRNA levels were significantly 
reduced in BLM-treated TG mice compared to BLM-treated WT littermates, with a trend to 
reduction in fibronectin mRNA in these same TG mice (Figure 6b).  These data show a 
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protective effect of VEGF-A165b within the lung when expressed particularly by the alveolar 
epithelium, supporting a potential for therapeutic application.  
To determine the effect of VEGF-A165b on the development of BLM-induced pulmonary 
fibrosis, WT C57/Bl/6 mice received oro-pharyngeal (OP) BLM with or without the additional 
intra-peritoneal (IP) delivery of rhVEGF-A165b. Importantly, in one arm of the study, to 
specifically address the potential therapeutic benefit of VEGF-A165b, the compound was 
delivered during the fibrotic rather than the inflammatory phase of the model (late VEGF-A165b 
group).   
IP injection of VEGF-A165b significantly reduced the development of pulmonary fibrosis in WT 
mice. This protective effect of VEGF-A165b was evident in the early VEGF-A165b (EV) and late 
VEGF-A165b (LV) groups suggesting a protective effect of VEGF-A165b (Figure 6c). Whilst the 
expression of fibronectin and pro-collagen-1α mRNA in whole lung tissue RNA extracts was 
significantly up-regulated in mice treated with BLM + Saline IP, the expression in both VEGF-
A165b IP groups was not significantly different from OP Saline-treated controls, supporting the 
notion that VEGF-Axxxa is pro-fibrotic and VEGF-Axxxb is protective. 
 
DISCUSSION 
Whilst VEGF-A has been implicated in the response of the lung to injury there are conflicting 
reports as to whether it functions as a contributory or protective factor(21, 22, 27, 28). Processes 
classically associated with VEGF-A are extremely restricted within the normal lung (14, 17, 18) 
which reflects the increasing recognition of VEGF as vital in the function and maintenance of 
non-endothelial cells (8, 9).  Cumulative evidence from several studies has suggested that the 
alternatively spliced VEGF-Axxxb isoforms may have opposing/inhibitory functions compared to 
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the conventional VEGF-Axxxa family(31) and appreciation of the existence of numerous VEGF-
A isoforms and their interaction with VEGF-A receptors and co-factors determining VEGF-A 
bioavailability, offers one potential explanation for these discrepant findings.  
We show that differential expression of VEGF-Axxxa and VEGF-Axxxb isoforms in the IPF lung 
can result in functional changes to the fibrotic process, and that ATII cell VEGF-A is critical for 
the development of fibrosis in a pre-clinical murine model. The finding that in this model fibrosis 
can be prevented or resolved by expression of the inhibitory isoform indicates that it is the 
VEGF-Axxxa family that is pro-fibrotic and the VEGF-Axxxb family is inhibitory/regulatory. This 
leads to two potential new therapeutic approaches for IPF – selective inhibition of VEGF-Axxxa 
or stimulation (or administration) of VEGF-A165b. The development of a specific VEGF-A165a 
antibody (48, 49) and small molecule splicing agents which alter the relative balance of VEGF-A 
isoforms (50, 51), could facilitate this.  
We have shown significant up-regulation of VEGF-A165b within IPF lung tissue compared to 
normal lung. This was particularly seen in both ATII cells and fibroblasts (outside the fibrotic 
foci) in the most severely fibrotic areas of the IPF. These data were obtained from patients with 
established disease suggesting that dysregulated fibrosis has occurred despite these changes. We 
speculate that the increase in VEGF-A165b is a compensatory mechanism that was insufficient to 
prevent inappropriate fibrosis in these patients, however in some patients at risk, fibrosis will be 
prevented.  Sequential lung tissue data to support this is not available as these patients present 
with established disease. However, increased VEGF-A165b in baseline plasma samples from 
patients with subsequent progression supports this hypothesis(38). In contrast, we found a 
significant reduction in panVEGF-A expression in the BALF of IPF patients by ELISA as 
previously observed (45-47) and VEGF-A165b levels were undetectable in identical BALF 
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samples. The nature of BALF collection from IPF lung would favour least affected areas and the 
greatest intensity of immunohistochemical staining for VEGF-A165b was in the most fibrotic 
areas. 
The isoform production switch, altering the ratio of VEGF-Axxxa to VEGF-Axxxb could be 
viewed as a contributor to disease, or as a protective response of the ATII and other cells, a 
regulatory mechanism to maintain homeostasis as we have previously postulated in the lung(10) 
and others in systemic sclerosis(52, 53). Interestingly, it has become clear that IPF is associated 
with multiple splicing changes, such as that required for VEGF-A165b(54, 55). 
VEGFR1 was down-regulated in IPF and expression was low in fibrotic fibroblasts, with 
additional trends towards a reduction in both VEGFR2 and NP1 expression in IPF. This may be 
due to the presence of increased VEGF-A165b that has been shown to cause down-regulation of 
VEGFR2, as it results in internalisation and degradation through the endosomal pathway(32). 
Although fibroblasts lack VEGFR2, historically considered the most biologically active of all the 
VEGF receptors(56), we demonstrated that recombinant VEGF-A proteins have differential 
effects on the proliferation, migration and ECM protein expression by these cells. Given that 
VEGF-A165b levels are raised in IPF, and VEGF-A165a stimulates pro-fibrotic effects in fibrotic 
fibroblasts, which were inhibited by VEGF-A165b, this could be a protective mechanism in IPF 
that is being overwhelmed by the other inflammatory processes being driven forward (57). 
VEGF-A has been shown to have both paracrine and autocrine effects on several cell types 
within the lung (6) (10, 15) (16). It is our opinion that whilst the statistically significant 
differences observed in fibroblast responses to VEGF-A isoforms might appear biologically 
modest, they could have important implications in a slowly progressive fibrosing disease such as 
IPF, in which tissue remodelling and disease progression is best observed over months and years. 
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Whilst in vitro studies utilizing co-cultures of IPF-derived alveolar epithelium and fibroblasts 
would be desirable to further study this mechanism, there are several recognized practical 
limitations to culturing IPF epithelial cells (58). 
 
In our initial studies of a pre-clinical pulmonary fibrosis model we sought to determine the 
critical source of VEGF-A. We demonstrated a significant amelioration of the fibrotic response 
in a specific doxycycline induced ATII cell VEGF-A deficient mouse showing that alveolar 
production of VEGF-A is required for fibrosis to occur. VEGFA was not completely absent in 
this model, which is likely to reflect the situation in the human lung. We did not find any 
evidence of vascular abnormalities in our model though functional vascular studies were not 
undertaken. This supports the widely accepted notion in the pathogenesis of IPF that is of 
initiation by recurrent epithelial injury(20).  
Using this same pre-clinical model, we explored the potential therapeutic benefit of IP rhVEGF-
A165b administration. The BLM-model of lung fibrosis has been characterized as having an early 
partially inflammatory phase followed by a fibrotic phase(44). In our study both early IP VEGF-
A165b and critically late IP VEGF-A165b, delivered specifically in the ‘fibrotic phase’ of the 
fibrosis model, resulted in significant amelioration of pulmonary fibrosis. In conjunction with the 
previous data this demonstrates that it is VEGF-Axxxa isoforms that are required for fibrosis. 
This data supports our hypothesis that the co-ordinated expression of VEGF-Axxxa and VEGF-
Axxxb isoforms is important in the development and progression of pulmonary fibrosis. 
Differential expression of these families of VEGF-A isoforms may explain, in part, some 
apparently contradictory studies describing VEGF-A as both a protective and contributory factor 
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in fibrogenesis. We describe for the first time the apparent protective effects of VEGF-Axxxb 
expression in pre-clinical models of pulmonary fibrosis, an effect that may occur due to 
differential effects on fibroblastic synthetic function. Our findings support a ‘non-angiogenic/non 
vascular’ role for VEGF-A in the fibrotic lung. Future studies are required to elucidate further 
mechanisms by which VEGF-Axxxb may inhibit fibrogenesis and to address factors that may 
regulate alternative splicing of the VEGF-A gene.  
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Figure Legends  
 
Figure 1: PanVEGF-A and VEGF-A xxxb expression in the lungs of patients with IPF 
a)PanVEGF-A RT-PCR of whole lung RNA extract using VEGF-A Exon2/3 For and 8b Rev primers (above) and 
Exon 7a For and 8b Rev primers (below) (n=5 normal lung and n=5 IPF lung). VEGF-A121a, VEGF-A165a and 
VEGF-A189a isoforms were identified by RT-PCR and verified by direct sequencing (see E1). L indicates 50bp 
marker. 
b)Quantitative RT-PCR (qRT-PCR) of panVEGF-A and VEGF-Axxxb  mRNA expression in whole lung tissue 
homogenates of normal (n=5) and IPF lung (n=5). No significant difference was detected in the expression of 
panVEGF-A or VEGF-A165b (unpaired t-test) isoforms between normal and IPF lung samples.  
c) PanVEGF-A and VEGF-A165b ELISA data from lung whole tissue lysates in normal (n=5) and IPF (n=5) 
subjects. There was no significant difference in panVEGF-A expression (unpaired t-test with Welch’s correction), 
but a significant increase in VEGF-A165b expression in the IPF lung was observed (****p<0.0001, unpaired t-test). 
Data presented as means with SEM.  
d) VEGF-A165b ELISA data from plasma samples of IPF patients. VEGF-A165b ELISA data from plasma samples of 
progressor (death or >10% decline in FVC at 12 months follow-up) and non-progressor IPF patients (xx). There was 
a significant difference in plasma levels of VEGF-A165b in progressors (n=10) compared to non-progressors (n=15) 
(*p<0.05, unpaired t-test). 
e) PanVEGF-A levels in bronchoalveolar fluid (BALF) of patients with IPF (n=15) compared to controls (n=13) 
using an antibody that does not discriminate between isoforms. Patient demographics were statistically comparable 
by unpaired t-test (E 2a) . PanVEGF-A BALF levels were significantly lower in the IPF group compared to control, 
**p<0.01, unpaired t-test with Welch’s correction. Data presented as means with SEM: Mean panVEGF-A 
expression in control group 85.7pg/ml +/- 17.1, n=13 vs IPF 18.0pg/ml +/- 6.1. VEGF-A165b expression was below 
the limit of detection in both IPF patients and controls (10pg/ml).  
 
f) PanVEGF-A and VEGF-A
165
b immunohistochemical staining: Intense staining of the alveolar epithelium was 
observed for both panVEGF-A and VEGF-A
165
b in normal and IPF lungs (least and most fibrotic designated as in 
Ashcroft et al., and Ebina et al.(59, 60)) (block arrows). Additional sites of localisation included vessel walls (open 
arrow heads), fibroblasts (FFo indicates the fibrotic focus), lymphocytes and alveolar macrophages (AM). Isotype 
IgG shown as negative control. Scale bar =10µm, original magnification x100. Lower magnification images are 
shown in E2B.   
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Figure 2: VEGF-A receptor and co-receptor expression in the lungs of patients with IPF  
a) Quantitative RT-PCR of VEGFR1,VEGFR2, NP1 and NP2 mRNA expression in whole lung RNA extracts of 
normal (n=5) and IPF lung (n=5). VEGFR1(*p<0.05, unpaired t-test) and NP1 (*p<0.05, unpaired t-test) mRNA 
expression was significantly up-regulated in the IPF lung. Data presented as mean fold change in expression (2^-
∆∆CT) with SEM, data analysis performed on ∆∆CT values. 
 
 b) VEGF-A receptor and co-receptor immunohistochemical staining: Intense staining of the alveolar epithelium was 
observed for VEGFR1, VEGFR2, NP1 and NP2 (block arrows) in both the normal and IPF lung. Additional sites of 
localisation included the vascular endothelium (open arrow heads), fibroblasts (FFo indicates the fibrotic focus), 
lymphocytes and alveolar macrophages (AM). Isotype IgG shown as negative control. Images taken at x40 
magnification, scale bars 25µm. Additional higher magnification images are shown in E3B. 
c) Expression of VEGFR1, VEGFR2, NP1 and NP2 in whole tissue lysates of normal (n=5) and IPF lung (n=5) by 
western blotting (above) with semi-quantitative densitometric analysis below. VEGFR1, VEGFR2, NP1 and NP2 
were expressed in both the normal and IPF lung. VEGFR1(*p<0.05) was significantly down-regulated in the IPF 
lung (unpaired t-test, data presented as mean densitometry score with SEM).  
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Figure 3: VEGFR and VEGF-A isoform expression in NF and FF 
 
a)Expression of VEGFR1, VEGFR2, NP1 and NP2 in NF and FF by western blotting with semi-quantitative 
densitometric analysis. Using glomerular endothelial cells as a positive control (Ctrl), bands were observed by 
western blotting that were consistent with the expression of VEGFR1, NP1 and NP2 in both NF and FF. Mature 
VEGFR2 protein was not expressed by NF or FF fibroblasts (data not shown). Semi-quantification of expression by 
densitometry demonstrated a significant reduction in the expression of VEGFR1 (*p<0.05) and NP2 (*p<0.05) in 
un-stimulated FF cultures compared to NF (data presented as means with SEM, NF: n=4, FF: n=4, n=3 or n=4 
shown, unpaired t-test).  
 
b)Western blot of phosphorylated MEK1/2 and phosphorylated p42/p44 MAPK (mitogen-activated protein kinase) 
expression in response to 24 hours of stimulation with VEGF-A165a (20ng/ml) or VEGF-A165b (20ng/ml). In the 
absence of mature VEGFR2 expression in NF and FF, the activation of known VEGF-A signaling pathways was 
explored. Stimulation of NF and FF led to the increased phosphorylation of MEK1/2 and p42/p44 in response to 
treatment of cells with VEGF-A165a or VEGF-A165b. For densitometric analysis see Fig. E4.   
 
c) Western blot of panVEGF-A and VEGF-A165b expression in NF and FF cell lysates with semi-quantitative 
densitometric analysis (data presented as means with SEM). Recombinant proteins were used as positive controls to 
highlight the specificity of the VEGF-A165b antibody in detecting VEGF-A165b proteins. The dotted line in the lower 
blot indicates where the blot has been manually cut and components images separately. VEGF-A165b proteins were 
significantly up-regulated in FF cell lysates compared to NF (n=3, *p<0.05, unpaired t-test). No significant 
difference in panVEGF-A isoform expression was shown (n=3, unpaired t-test).   
 
d) Quantification of protein expression of panVEGF-A and VEGF-A165b expression in NF and FF cell lysates. By 
ELISA there was no significant difference in the expression of panVEGF-A  or VEGF-A165b in NF or FF cell lysates 
(n=6 performed in duplicate cell lysates of different passage, unpaired t-test). In the conditioned medium extracted 
from these cultures panVEGF-A expression was significantly up-regulated in the FF supernatants (n=6, *p<0.05, 
unpaired t-test)-see Fig E7. VEGF-A165b expression in these same cell supernatant samples was below the limit of 
detection of the ELISA (10pg/ml). 
 
e) Cell immunofluorescence of panVEGF-A and VEGF-A165b expression in NF and FF. Comparable patterns were 
observed for NF and FF, with cytoplasmic, and perinuclear expression of panVEGF-A and cytoplasmic expression 
of VEGF-A165b. Images taken at x40 magnification with scale bar indicating 25µm. Primary antibody shown in 
green with an overlay image of the primary antibody, phalloidin (red) for F-actin and DAPI (blue) for nuclear 
staining. Isotype IgG controls and separate phalloidin and DAPI images shown in supplementary data (E8).  
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Figure 4: Functional response of NF and FF to recombinant VEGF-A proteins 
a)The effect of VEGF-A on the expression of fibronectin (FN) by NF and FF in response to 24 hours of stimulation 
with VEGF-A165a (20ng/ml) or VEGF-A165b (20ng/ml) as measured by western blotting (above) with densitometry 
analysis (below). A significant increase in the expression of FN in response to VEGF-A165a stimulation in both 
NF(**p<0.01 with 10ng/ml and 20ng/ml) and FF (
+++
p<0.001 at 20ng/ml, n=3) was observed. There was no 
significant effect of VEGF-A165b on the expression of FN in neither NF or FF. 
b)The combined effect of VEGF-A165a and VEGF-A165b on the expression of FN in NF and FF as measured by 
western blotting (above) and densitometry (below). Used in isolation, VEGF-A165a (20ng/ml) was shown to increase 
FN expression in NF (
X 
p<0.05) and FF (
XX
p<0.01), whilst VEGF-A165b had no significant effect, as shown in the 
previous experiments. VEGF-A165b inhibited the VEGF-A165a-induced increase in FN expression in both NF 
(*p<0.05 at 40ng/ml of VEGF-A165b) and FF (
+++
p<0.001 at 10, 20 and 40ng/ml of VEGF-A165b) with FF appearing 
to be more susceptible to this effect (n=3). Data presented as means with SEM.  
c) The effect of VEGF-A on the expression of collagen by NF and FF in response to 24 hours of stimulation with 
VEGF-A165a or VEGF-A165b as measured by HPLC.. In the presence of both isoforms, VEGF-A165b inhibited 
collagen production in NF but not FF (*p<0.05, **p<0.01) (NF and FF n=3). Data presented as means with SEM.  
d) The effect of VEGF-A recombinant proteins on the proliferation of NF and FF: A significant increase in FF cell 
number was observed in response to 20ng/ml VEGF-A165a compared to SFM (
X
p<0.05). VEGF-A165a-induced 
proliferation was inhibited by the concomitant addition of 20ng/ml VEGF-A165b (
+++
p<0.001) or 10ng/ml sFlt 
(
+++
p<0.001). VEGF-A165a had no statistically significant effect on NF cell proliferation compared to SFM, but 
concomitant treatment of NF with 20ng/ml VEGF-A165a and 20ng/ml VEGF-A165b (*p<0.05) or sFlt (*p<0.05) 
inhibited cell proliferation compared to 20ng/ml VEGF-A165a alone (*p<0.05) (NF and FF n=5). Data presented as 
means with SEM.  
e) The effect of VEGF-A recombinant proteins on NF and FF wound healing. Image analysis performed using 
Image J. VEGF-A165a and VEGF-A165b significantly increased the migration of NF at 48 hours (*p<0.05). This 
effect was blocked by the concomitant treatment of VEGF-A165a and VEGF-A165b. Recombinant VEGF-A proteins 
had no significant effect on the migration of FF. Statistical analysis: ANOVA with post-hoc Holm’s Sidak multiple 
comparisons analysis used throughout (n=4). Representative images shown in E9. 
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Figure 5: The effect of post-natal deletion of VEGF-A from ATII cells on the development 
of pulmonary fibrosis 
a) GFP-eporter mice (ROSA
mT/mG
) were crossed with SPC
+/-
TC
+/-
LoxP
+/- 
TG mice (STCL) to determine the period of 
doxycycline induction required to activate the Cre-recombinase and to identify the tissue specificity of Cre-
recombinase activity following doxycycline induction. The reporter mice possess LoxP sites on either side of a 
membrane-targeted tdTomato (mT) cassette and express red fluorescence in all tissues. In the presence of Cre 
recombinase, the mT cassette is deleted allowing expression of the membrane-targeted EGFP (mG) cassette located 
just downstream. The in vivo imaging system (IVIS) demonstrated evidence of GFP fluorescence in the GFP-STCL 
mouse following 10 weeks of doxycycline induction, absent at 4 weeks of induction and in WT mice. Direct 
visualisation of the lungs of induced mice (at 12 and 14 weeks of doxycycline treatment), demonstrated GFP 
fluorescence in ATII cells with an absence of GFP fluorescence in the bronchial epithelium (14 weeks induction 
image, arrows). Images taken at x40 magnification, scale bar 25µm, n=3. GFP fluorescence was absent in the 
kidneys and liver (see supplementary data E10). Using a murine VEGF-A RNA probe, in situ hybridisation 
demonstrated a reduction in ATII cell staining (reduction in blue/black signal) in induced-TG mice compared to 
induced-WT mice (arrows). Pink staining represents nuclear fast red counterstain (n=3, images taken at x100 
magnification, scale bar = 10µm). PanVEGF-A mRNA expression was significantly reduced in whole tissue RNA 
extracts from TG mice compared to WT mice (n=6, **p<0.01, unpaired t-test, data presented as means with SEM). 
Consistent with these findings, immunohistochemical staining for panVEGF-A also showed a reduction in ATII cell 
staining in induced-TG mice compared to induced-WT mice (n=3, images taken at x100 magnification, scale bar = 
10µm).  
b) Post-natal deletion of VEGF-A from ATII cells ameliorates the development of BLM-induced pulmonary 
fibrosis. Masson’s Trichrome staining of mouse lung sections, with lung fibrosis score and quantitative RT-PCR of 
FN and pro-collagen-1α mRNA levels above (below). As demonstrated by Masson’s Trichrome staining, 
administration of BLM to both WT (g-i) and non-induced STCLL (j-l) mice resulted in extensive pulmonary 
fibrosis. This effect was ameliorated in BLM-treated doxycycline-induced STCLL mice (m-o). Images originally 
x10 magnification, scale bar = 100µm, n=5 or 6, n=3 shown). The lung fibrosis score of BLM-treated, doxycycline-
induced STCLL mice was significantly reduced compared to BLM-treated controls (induced-WT mice **p<0.01 
and non-induced STCLL mice **p<0.01, n = 5).The expression of FN and pro-collagen-1α mRNA was significantly 
up-regulated in the lungs of BLM-treated, doxycycline-induced WT mice compared to saline treated controls 
(****p<0.001, n=5 or 6 analysed). FN and pro-collagen-1α expression was significantly up-regulated in BLM-
treated, doxycycline-induced TG mice compared to TG saline controls (*p<0.05, **p<0.01, n=5). Furthermore, FN 
mRNA levels were significantly reduced in BLM-treated TG mice compared to BLM-treated WT mice (*p<0.05, 
n=5), with a trend towards a reduction in pro-collagen-1α levels in these same mice (p=0.08, n=5). Statistical 
analysis: ANOVA with Holm’s Sidak multiple comparisons test used throughout.  
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Figure 6: The effect of VEGF-A165b on the development of pulmonary fibrosis. 
a) Lung phenotype of the MMTV-VEGF-A165b TG mouse: Immunohistochemical staining for VEGF-A165b in the 
lung of TG mice with quantification of VEGF-A165b expression by ELISA, in whole tissue lysates and BALF fluid. 
VEGF-A165b expression was increased in the ATII cells of the TG mouse lung ((d +f) indicated by arrows) 
compared to the WT lung (c+e). Isotype IgG staining was used as a negative control (a+b). Images taken at x100 
magnification, scale bars 10µm, (n=3, n=1 shown). VEGF-A165b expression was significantly up-regulated in whole 
tissue lysates of TG mice compared to WT mice (*p<0.05, unpaired t-test with Welch’s correction, n=4). The 
expression of VEGF-A165b was below the limit of detection of the ELISA in all BALF samples of WT mice but 
present in detectable levels in all BALF samples of TG mice. There was no statistical difference between these 
groups (p=0.055, unpaired t-test with Welch’s correction, n=4).  
b) Over-expression of VEGF-A165b in ATII cells ameliorates the development of BLM- induced pulmonary fibrosis. 
Representative images of Masson’s Trichrome staining with lung fibrosis score and quantitative RT-PCR of FN and 
pro-collagen-1α mRNA levels (below). Masson’s Trichrome staining of mouse lung sections, 21 days following OP 
instillation of BLM to MMTV-VEGF-A165b TG mice (j-l) or littermate controls (g-i). The development of BLM-
induced pulmonary fibrosis was ameliorated in TG mice. Saline controls demonstrated in (a-f), (n=6 per group, n = 
3 shown). Scale bar 100µm, original magnification x10. The lung fibrosis score of BLM-treated TG mice was 
significantly lower than BLM-treated WT mice (***p<0.001, n=6 per group). FN mRNA was significantly up-
regulated in the lungs of WT BLM-treated mice compared to WT-saline treated controls (**p<0.01, n=6 analysed) 
and in TG BLM-treated mice compared to TG saline-treated controls (*p<0.05) (n=6). There was no statistical 
difference between BLM-treated WT and TG mice (p=0.09, n=6). In contrast, pro-collagen-1α mRNA levels were 
significantly reduced in BLM-treated TG mice compared to BLM-treated WT littermates *p<0.05, n=6). Data 
presented as means with SEM. Statistical analysis: ANOVA with Holm’s Sidak multiple comparisons test used 
throughout. 
c) IP instillation of rhVEGF-A165b ameliorates the development of pulmonary fibrosis. Masson’s Trichrome staining 
of lung sections with lung fibrosis score and quantitative RT-PCR of FN and pro-collagen-1α mRNA levels (below). 
Representative images of Masson’s Trichrome staining of mouse lung sections, 21 days following OP instillation of 
Bleomycin with or without additional IP  rhVEGF-A165b instillation: (a-c) OP Saline control (no differences 
between Early IP VEGF-A165b (EV) or late IP VEGF-A165b (LV) plus saline), (d-f) OP Bleomycin with saline IP (g-
i) Early IP VEGF-A165b treatment with subsequent Bleomycin OP instillation (j-l) Bleomycin OP with subsequent 
late IP VEGF-A165b instillation. Early and late rhVEGF-A165b instillation ameliorated the development of lung 
fibrosis (n=6 per group, n=3 shown). Scale bar 100µm, original magnification x10. By qRT-PCR FN and pro-
collagen-1α mRNA was significantly up-regulated in the lungs of BLM-treated mice compared to saline-treated 
controls (*p<0.05, **p<0.01, n=5). In contrast, FN and pro-collagen-1α expression in mice treated with either early 
(EV) or late (LV) rhVEGF-A165b and BLM was not significantly different to saline control (n=6). The lung fibrosis 
score in both early (EV, **p<0.01) and late (LV, *p<0.05) IP rhVEGF-A165b treatment groups was significantly 
reduced compared to BLM OP-Saline IP treated mice, n=5 or 6 per group, data presented as means with SEM. 
Statistical analysis: ANOVA with Holm’s Sidak multiple comparisons test used throughout.  
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Materials and Methods 
Human tissue collection  
Anonymised human lung biopsies were donated from patients undergoing clinically 
indicated open or VATS thoracoscopy. Tissue surplus to diagnostic requirements with a 
histopathological appearance of either normal alveolar tissue or a pattern of UIP (for patients 
with IPF) was accepted. The institutional review boards of both North Bristol and United 
Bristol Healthcare Trusts granted ethical approval. Written informed consent was obtained 
from each patient. Additional IPF lung samples were donated from the Lung Tissue Research 
Consortium (LTRC), USA. 
Bronchoscopy and Bronchoalveolar lavage (BAL) were performed according to 
standard protocols. These were not performed on the subjects from whom the lung tissues 
were obtained. The BAL fluid (BALF) was immediately spun at 500g for 5 min and 
supernatant was collected and stored at −80°C until required. 
Plasma samples were donated by Toby Maher, Royal Brompton hospital. These were 
obtained as additional samples to the PROFILE study and classified as stable vs progressors 
as described previously (ref: E1) 
Primary lung fibroblast culture 
Primary lung fibroblasts were explanted from whole lung tissue biopsies using 
established techniques and cell cultures maintained under standard growth conditions (37°C 
in a humidified atmosphere consisting of 95% air and 5% CO2) in DMEM-F12 media 
(Gibco) supplemented with 1% Fungizone (Gibco), 1% penicillin/streptomycin (Sigma, 
P43330) and 10% Heat inactivated Newborn Calf Serum (Gibco). 
Additional IPF fibroblast cultures were donated (Toby Maher, Royal Brompton 
Hospital). Normal and IPF fibroblast cultures (ATCC, American Type Culture Collection) 
were also purchased.  
Stimulation of NF and FF with rhVEGF-A165a or rhVEGF-A165b:  
For all experiments cells were grown to 80% confluence in T25 Corning flasks, prior 
to induction of cell quiescence in SFM for 24 hours.  
To determine NF and FF fibronectin expression, confluent, growth arrested cells were 
treated with serial concentrations of rhVEGF-A165a (Cell Signaling) or rhVEGF-A165b (R&D) 
alone and in combination for 24 hours. mRNA and protein were isolated for analysis by qRT-
PCR (n=4) and western blotting (n=3), respectively.  
To determine the signalling characteristics of pulmonary fibroblasts in response to 
VEGF-A recombinant proteins, cells were then incubated for 10 minutes with either a) SFM, 
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b) rhVEGF-A165a 20ng/ml or c) rhVEGF-A165b 20ng/ml, prior to lysis in RIPA buffer for 
protein analysis. 
 
 
RT-PCR for detection of VEGF-A isoforms 
Total RNA was isolated from human lung tissue or fibroblast lysates using the Quick 
RNA
TM
 mini prep kit (R1054, Zymo Research), as per manufacturer’s instructions to prevent 
gDNA contamination. RNA, 0.4-1µg, was reverse transcribed into cDNA using the Taqman 
High Capacity RNA-to-cDNA kit (Applied Biosystems). cDNA was subjected to PCR with 
one of two primer sets: Forward primer 5’-CGA AGT GGT GAA GTT CAT GGAT G-3’, 
spanning exon 2/3 and reverse primer 5’-TTCTGTATCAGTCTTTCCTGGTGA-3’, located 
within the 3’UTR of exon 8b or Forward primer: 5’-GTTTGTACAAGATCCGCAGACGT-
3’ located within exon 7a and the same reverse primer 5’-
TTCTGTATCAGTCTTTCCTGGTGA-3’, located at the 3’UTR of exon 8b. VEGF-A165a 
and VEGF-A165b plasmid templates (pcDNA3-VEGF-A165a or pcDNA3-VEGF-A165b) (1µl 
of 0.1ng/µl) were used as positive controls. An additional reaction was carried out with a 1:1 
mix of each template (0.5µl of 0.1ng/µl of each template) to demonstrate that the RT-PCR 
reaction could amplify both templates if present. Samples were run in 1xTAE buffer and then 
bands excised for direct sequencing. 
RT-PCR was also used to demonstrate human VEGF-A165b expression in the TG 
MMTV-165b mouse lung, the human panVEGF-A primers: exon 7a For and 8b Rev were 
used, in addition to primer sets that specifically detected the presence of the MMTV-
VEGF165b transgene: For (exon 7): 5’- ACA AGA TCC GCA GAC GTG TA-3’, Rev (Poly-
A tail): 5’- ACA GAT GGC TGG CAA CTA-3’. 
Quantitative RT-PCR  
Total RNA was isolated and reverse transcribed into cDNA as described above. 
Individual qRT-PCR reaction mixes were made according to manufacturer recommendations 
(2x SensiFAST SYBR Hi-ROX (Bioline)).  
Human and murine primer sets used are detailed in Supplementary Tables 1 and 2, 
respectively. Using a qPCR method previously published by Varey et al (ref:E2), the 
expression of human VEGF-Axxxa and VEGF-Axxxb isoforms were also quantified. Primer 
sequences available upon request.  
The standard cycling regime used consisted of: 95
o
C for an initial 2 mins, followed by 
thermal cycles of 95
o
C for 5 secs and 60
o
C for 30 secs, for 50 cycles for identification of 
VEGF-A isoforms and 40 cycles for all other products. Minus reverse transcriptase and non-
template control reactions were additionally performed as negative controls. The expression 
level of each gene was normalised to β-actin expression, for human samples or HPRT for 
murine samples. The specificity of the PCR-products was confirmed by melt-curve analysis.  
Fluorescence data from each sample were analysed with the 2
-∆∆Ct 
method, where ∆∆Ct = (Ct 
GI unknown sample – Ct Actin unknown sample) – (Ct GI calibrator sample – Ct Actin 
calibrator sample), where GI is the gene of interest. Statistical analyses were performed on 
∆∆CT values.Cell Immunofluorescence 
Cells were grown to 80% confluence on sterile glass coverslips. Cells were fixed for 
10 minutes in 2% paraformaldehyde in PBS. Cells were permeabilised in with 0.3% TritonX-
100 (Fischer Scientific) and blocked in a 5% HI NCS (Gibco), 2% BSA (Fischer Scientific, 
BPE) and 0.1% Tween x20 (Sigma) in PBS for 30 minutes. Cells were incubated with the 
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primary antibody of interest, overnight at 4˚C. Primary antibodies were prepared at a 
concentration of 1 in 50 in blocking solution: VEGFR1(AbCam), VEGFR2 (Cell Signaling), 
NP1 (AbCam), NP2 (Santa Cruz), panVEGF-A (Santa Cruz) and VEGF-A165b (AbCam). 
The following day, cells were incubated with the appropriate secondary antibody for 
one hour: Invitrogen Alexa Fluor 488 Goat anti-mouse IgG or Invitrogen Alexa Fluor Goat 
anti-rabbit IgG at a concentration of 1 in 200 in blocking solution. DAPI (4',6-diamidino-2-
phenylindole)  (Invitrogen) and Phalloidin 568 (Invitrogen) were used as counterstains for 
nuclear and F-actin, respectively. Mounted coverslips were examined using a Leitz DMRB 
fluorescent microscope (Leica, Solms, Germany) and images captured (Leica EL6000 digital 
camera and Leica Application Suite Advanced Fluorescent (LASAF) software). Comparison 
of overlaid images enabled identification of cellular expression. 
 
Western-Blot Analysis 
Cell lysates were prepared from fibroblast cultures (Passage (P) 2-7), using RIPA 
(radio-immunoprecipitation) extraction buffer (Sigma, R0278), containing 1:100 protease 
inhibitor cocktail (Sigma) and 1:100 phosphatase inhibitors (Sigma). Whole lung tissue 
lysates were prepared in Triton-X100 containing protease and phosphatase inhibitors. Cell 
lysate protein was quantified using a BCA (bicinchoninic acid) protein assay kit (Fischer 
Scientific) as per the manufacturer’s guidelines.  
Protein (30-45µg) was loaded into 8-12% acrylamide gels and  transferred to 
PolyVinylidine DiFluoride (PVDF, Millipore 0.45µm) membrane, incubated in blocking 
buffer (5% non-fat dried milk in 1 X TBST) for one hour and then in primary antibody 
overnight. Primary antibodies: VEGFR1 (Abcam), VEGFR2 (Cell Signaling), NP1 (Abcam), 
NP2 (Santa Cruz), panVEGF-A (Santa Cruz) and VEGF-A165b: donated by D.O.Bates, 
Fibronectin: (BD Transduction labs), Phospho MEK1/2 (Cell Signaling), Phospho p42/p44 
(Cell Signaling), Lamin (Cell Signaling), β-Actin (Sigma), Tubulin (Sigma), GAPDH 
(Millipore). 
 Membranes were then incubated with a HRP-conjugated secondary antibody (donkey 
anti-rabbit or sheep anti-mouse GE Healthcare) in blocking buffer for 1 hour prior to 
visualisation by means of luminol-enhanced chemiluminescence (SuperSignal, West Femto, 
34096, Thermo Scientific) and imaged with a UVP ChemiDoc-It imaging system (UVP, 
California, USA) and Visionworks LS software. Equal protein loading per lane was 
confirmed using β-actin, GAPDH or tubulin controls.  
Lysates from conditionally immortalised glomerular endothelial cells (P20) were used 
as a positive control for VEGF receptor expression, whilst recombinant rhVEGF-A165a (Cell 
Signaling) and rhVEGF-a165b (R&D) proteins provided positive controls for VEGF-A 
isoform expression. Semi-quantification of protein expression was undertaken by 
densitometry using Image-J software.   
Immunohistochemistry 
Slides were de-waxed in xylene prior to rehydration of tissue in decreasing 
concentrations of ethanol, then rinsed in dH2O prior to antigen retrieval in sodium citrate 
buffer (10mM Sodium citrate in 0.05% Tween 20, pH6). For the localisation of NP2 in 
human tissues a TRIS-EDTA (10mM Tris Base, 1mM EDTA, 0.05% Tween, pH9.0) antigen 
retrieval buffer was used. Endogenous peroxidases were blocked with 30% hydrogen 
peroxide (H2O2) (Sigma) in Methanol (Fisher Scientific) and dH2O, washed, then blocked 
with 2.5% normal horse serum (NHS)(provided in Vector IMMPRESS reagent kits). Sections 
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were incubated with primary antibody (concentration of 1:100 in 2.5% NHS block) or 
appropriate IgG control. 
Slides were washed in TBS before addition of secondary antibody (Vector 
IMMPRESS reagent kit (peroxidase) anti-mouse IgG (MP7402) or anti-rabbit (MP7401), 
washed and substrate (Vector NovaRED substrate kit for peroxidase) added until a red colour 
was visible and |counterstained with Haematoxylin (Vector).  
For dual stained sections: Following completion of the substrate step, sections were 
blocked in 2.5% NHS. Slides were incubated in the second primary antibody (E-Cadherin – 
diluted 1:50 in 1% BSA in PBS) then washed and the secondary antibody applied (anti-
mouse IgG polymer HRP – Vector) as per manufacturer instructions. The SG Peroxidase 
substrate kit was applied (Vector) then rinsed with dH2O.  
Slides were dehydrated and then cleared in xylene (4 mins) before mounting and 
subsequent imaging (Leitz DMRB microscope (Leica, Solms, Germany) using the Leica 
EL6000 digital camera and Leica Application Suite Advanced Fluorescent (LASAF) 
software). 
ELISA of PanVEGF-A and VEGF-A165b 
Protein was isolated from fibroblast cell cultures using RIPA buffer (Sigma) and 
protein quantified by BCA analysis (Thermo Scientific, Pierce). Human lung tissue was 
initially weighed (wet weight) and protein isolated using mechanical homogenisation in 1% 
Triton extraction buffer containing protease and phosphatase inhibitors. Commercially 
available ELISA kits were used to quantify panVEGF-A (R&D systems) and VEGF-A165b 
levels (R&D systems) in BALF, human lung tissue, fibroblast cell lysates,  cell supernatants 
and plasma according to manufacturer’s instructions. 
Cell Proliferation assay 
Fibroblasts were seeded into 24-well plates (Nunc) at 30,000 cells in complete 
medium. After 24 hours cells were quiesced in SFM for 24 hours then incubated in either 
SFM, complete medium (GM), 5ng/ml VEGF-A165a, 20ng/ml VEGF-A165a +/- 10ng/ml sflt 
in SFM, 10ng/ml sflt alone, 20ng/ml VEGF-A165b or 20ng/ml VEGF-A165a +20ng/ml VEGF-
A165b, in triplicate wells for a further 48 hours. Cells were then trypsinised, stained with 
Trypan Blue (Lonza) and manual live cell count performed using a haemocytometer.  
Wound healing - Migration assay  
Fibroblasts were seeded into Ibidi culture chambers (Ibidi GmbH Munich, Germany), in 
complete culture medium (30,000 cells per chamber) and grown to confluence. Cells were 
then quiesced for 24 hours in SFM prior to treatment with either SFM alone, complete 
medium (GM), 20ng/ml VEGF-A165a, 20ng/ml VEGF-A165b or a combination of 20ng/ml 
VEGF-A165a +20ng/ml VEGF-A165b for 48 hours. Images were taken with the Leica EL6000 
digital camera and Image Pro Capture Software with Image J analysis.  
 
High performance liquid chromatography (HPLC) 
Fibroblasts were seeded in DMEM/10% FBS at 1x10
5
 cells per well in 6-well plates. After an 
overnight incubation, the medium was replaced with collagen pre-incubation medium 
containing 4mM glutamine, 50µg/ml ascorbic acid, 0.2mM proline and 0.4% FBS for 24 
hours. Cells were then stimulated with VEGF-A165a, VEGF-A165b or a combination thereof. 
After a further 24 hours, plates were subjected to a freeze/thaw cycle to lyse cells; the well 
contents were collected, following scraping of the cell layer, and proteins were precipitated 
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with 20% trichloroacetic acid. The protein pellet was spun down, washed with 80% ethanol 
and air dried prior to hydrolysis with 200µl of 6N HCl at 100°C for 18 hours. An aliquot of 
acid hydrolysate was dried using a vacuum concentrator and hydroxyproline content was 
quantified by reverse-phase HPLC following 4-Chloro-7-nitro-1,2,3-benzoxadiazole 
derivatization; the amount of collagen was calculated assuming that collagen contains 12.2% 
(w/w) hydroxyproline. 
 
Animal housing and breeding 
All experiments were carried out in accordance with the UK Animals (Scientific 
Procedures) Act 1986 and with approval of the University of Bristol ethical review panel. All 
mice were housed in pathogen free facilities in line with Home Office regulations in separate 
cages, in a temperature-controlled room and with alternating 12-hr:12-hr light/dark cycles. 
Animals were fed a standard diet unless otherwise stated.  
Thirty female wild-type (WT) C57Bl6 mice were purchased from Charles River 
Laboratories (Margate, UK), aged 8-10 weeks. Adult GFP-reporter breeding males  
(Rosa
mT/mG
) were kindly donated by Dr Richard Coward, University of Bristol. 
TG mice constitutively over-expressing VEGF-A165b in the lung (MMTV-
VEGF165b
+/
) were generated as previously described. This line was originally generated on a 
C57Bl6xCBA/CA background then backcrossed with C57/BL6 mice for more than 10 
generations (ref:E3). Adult female mice were used for all studies and WT littermate controls 
were used for comparison.  
SPC-rtTA
+/-
Tet-O-Cre
+/-
LoxP VEGF
+/+ 
mice were generated on a C57Bl6 background 
by crossing three transgenic mouse lines. LoxP-VEGF: A TG mouse line with LoxP sites 
inserted around the third exon of VEGF-A (Genentech, San Franscisco, USA). In this mouse, 
site-specific recombination between LoxP sites results in a null VEGF-A allele (ref:E4). A 
second TG strain carried the target gene, Cre-recombinase, under the regulatory control of a 
tetracycline-responsive promoter element (Tet-O) and was generated by Dr Andras Nagy and 
Marina Gertsenstein (Mount Sinai Hospital). In this construct, the target gene is only 
expressed in the presence of the tetracycline analog, Doxycycline. Finally, heterozygous, 
male TG mice expressing the reverse tetracycline-controlled transactivator (rtTA) protein 
under the control of the 3.7 kb human SFTPC, surfactant, pulmonary-associated protein C, 
promoter (SPC mice), were purchased from Jackson Laboratory (Strain Name B6.Cg-
Tg(SFTPC-rtTA)5Jaw/J, Stock Number 006235, Bar Harbor, ME). Previous characterisation 
of this mouse strain has demonstrated that this promoter directs targeted gene expression 
within ATII cells and the distal conducting airways (ref:E5). Upon administration of 
doxycycline chow (Harlan, TD 01306, 625mg/kg doxycycline hyclate), it was predicted that 
transcription of the Cre-recombinase was induced only in cells where the rtTA was 
expressed, initiating site specific recombination between Lox-P sites with deletion of all 
VEGF-A isoforms, specifically in respiratory ATII cells. 
During the breeding of TG mice, genomic DNA (gDNA) was extracted from ear 
notches of weaned pups and was screened for the existence of transgene by PCR. Details of 
primers sets and PCR cycling conditions for each transgene are available upon request.  
 
Animal studies 
To determine the timing and site specificity of doxycycline-induced Cre 
recombination in our TG model, ROSA
mT/mG+/+ 
reporter mice were bred with S
+/-
TC
+/-
LoxP
+/-
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mice (GFP-STCL). The TG construct consists of LoxP flanked fluorescent tomato protein 
(mT) upstream of Green Fluorescent Protein (GFP), under the control of a chicken beta actin 
promoter (pCA). When bred to Cre recombinase expressing TG mice, the mT cassette is 
deleted in Cre expressing tissues of the resulting offspring, allowing expression of the 
membrane-targeted GFP (mGFP) cassette located immediately downstream. GFP-STCL mice 
(n=5) and littermate controls (n=5) were induced with doxycycline chow (Harlan, TD 01306, 
625mg/kg doxycycline hyclate) for a minimum period of 10 weeks. During this induction 
period, anaesthetised mice were imaged for the presence of GFP-lung fluorescence, using an 
IVIS Spectrum whole animal in vivo imaging system (Xenogen, Hopkinton, MA), initially at 
4 weeks and then every 2 weeks thereafter. Mice were imaged lying prone, in addition to on 
their left and right sides.  
To maximise the GFP-fluorescent signal, hair was removed from the thoracic area of 
each mouse using depilatory cream (Nair, Church & Dwight) prior to imaging. One control 
and one experimental mouse were imaged simultaneously and the acquired images were 
analysed using Live Image software (version 2.5), normalising for auto-fluorescence from the 
animal body itself to provide a quantitative fluorescent signal. Upon detection of GFP-lung 
fluorescence by IVIS imaging, the presence of GFP fluorescence was confirmed by direct 
visualisation of sectioned lung tissue. 
Lung samples from GFP reporter mice were embedded and frozen in (TissueTek), 
prior to sectioning (5µm, Superfrost slides). The liver and kidneys were also prepared in the 
same way to provide tissue controls. For direct immunofluorescence sections were fixed in 
4% PFA, washed in 1XPBS then mounted with coverslips using Vectashield mountant 
containing DAPI (Vectashield, H-1200). Slides were imaged using Leica EL6000 digital 
camera and Leica Application Suite Advanced Fluorescent (LASAF) software. 
In situ hybridisation 
Dissected lung samples for in-situ hybridisation were fixed in 4% PFA overnight 
(Alfa Aesar) at room temperature (RT), then immersed in 30% sucrose in PBS. Lungs were 
snap frozen in OCT (Sakura) and sectioned at 5µm onto poly-l-lysine slides (Sigma) and 
stored at -80°C.   
Slides were air-dried then treated with 15µg/ml Proteinase K (Sigma P2308). Slides 
were washed Hyclone-PBS (Thermo-Scientific) and then  then fixed in 4% PFA prior to 
sequential washing in DEPC-PBS and 2xSSC (Roche) (pH7).Sections were pre-hybridised in 
pre-heated hybridisation buffer in a 50% Formamide (Roche)/5xSSC humidified chamber, 
and incubated overnight at 60°C with sense (negative control) and anti-sense VEGF-A RNA 
probes (1µg/ml)(kind gift from S. Quaggin).  
The following day, slides were rinsed in 2 x SSC, followed by washes in 50% 
formamide/0.2% x SSC. Sections were then washed twice in 2 x SSC, followed by a 5 minute 
wash in NT buffer (pH7.5).  Sections were incubated in NT blocking buffer prior to the 
addition of an anti-DIG AP Fab fragment antibody (Roche). Slides were washed twice in 
TBSTL then in APB buffer. BM purple AP colour substrate (Roche) was applied to sections, 
slides wrapped in foil and incubated in a humidified chamber overnight. The following day 
slides were washed in dH2O prior to immersion in Nuclear Fast Red (Vector) counterstain 
.Slides were rinsed in tap water then dehydrated through increasing concentrations of ETOH 
and cleared in xylene. Sections were mounted with DPX mountant (Sigma) and coverslips 
prior to imaging.   
Bleomycin-induced model of pulmonary fibrosis  
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The Bleomycin-induced murine model of pulmonary fibrosis was used to investigate 
the possible role of VEGF-A in lung fibrogenesis. Mice (10-12 weeks) were anaesthetised 
with inhalation of 2% isoflurane prior to the administration of Bleomycin (50IU per mouse in 
50µL sterile 0.9% Saline, Bleo-Kyowa; gift from Kyowa Hakko Ltd, Slough, UK) or an 
equivalent volume of sterile 0.9% Saline vehicle, by an oro-phrayngeal instillation technique 
(ref:E6). Adult SPC-rtTA
+/-
Tet-O-Cre
+/-
LoxP VEGF
+/+
 mice (6-8 weeks old) received 
doxycycline chow for 12 weeks (TD 01306, 625mg/kg doxycycline hyclate, Harlan, UK) 
prior to the administration of BLM. Body weight and well-being was monitored on alternate 
days. Mice were culled at 21 days by Schedule 1 methods and samples harvested. The lungs 
were lavaged using 3 x 1ml instillations of 0.9% sterile Saline, each withdrawn via an intra-
tracheal catheter (22 Gauge, Bioflon). Lavage fluid was centrifuged at 13,000 rpm for 5 
minutes to clear cells, the supernatant was removed then stored at -80
o
C. 
The heart and lungs were removed en-bloc. The right lung was tied off and snap 
frozen in liquid nitrogen, whilst the left lung was inflated under gravity with 10% neutral-
buffered formalin (Sigma), incubated in the same solution overnight at 4
0
C, prior to paraffin 
wax embedding and sectioning (5µm, Superfrost slides).  
Determination of lung fibrosis 
Lung fibrosis was assessed histologically by Masson’s Trichrome staining and lung 
fibrosis score. Quantification of lung fibronectin and pro-collagen-1α mRNA expression 
provided additional supportive information.  
Masson’s Trichrome staining 
Slides were de-waxed in Xylene (Sigma) for 6 mins prior to rehydration of tissue in 
decreasing concentrations of Ethanol. The slides were rinsed in dH2O, then allowed to 
mordant in Bouin’s Solution (Sigma) overnight in a fume extraction hood. Slides were 
washed in running tap water and then rinsed in dH2O.,then immersed in Weigert’s Iron 
Haematoxylin (made fresh by adding equal volumes of Solution A (1% Haematoxylin in 95% 
ETOH) and Solution B (1.2% Ferric Chloride and 1% Acetic Acid in dH2O)(Sigma), staining 
nuclei blue-black. Slides were washed and rinsed in de-ionised water prior to immersion in 
Biebrich Scarlet-Acid Fuchsin stain (Sigma, Accustain Trichrome stain kit, 0.9% Biebrich 
scarlet, 0.1% Acid Fuchsin and 1% Acetic Acid) for 5 minutes, staining cytoplasm and 
muscle red. The slides were washed in dH2O and immersed in freshly prepared 
Phosphotungstic / Phosphomolybdic Acid Solution (1:1 volume)(Sigma, Accustain 
Trichrome stain kit, 10% Phosphotungstic Acid and Phosphomolybdic Acid solution), 
providing the acidic environment required for uptake of the Aniline Blue stain.  Sections 
were then stained in Aniline Blue (Sigma, Accustain Trichrome stain kit, 2.4% Aniline Blue, 
2% Acetic Acid), staining collagen blue. Slides were rinsed in dH2O prior to immersion in 
1% Acetic Acid solution (Fischer Scientific) to differentiate the blue stain and then rapidly 
dehydrated before clearing in Xylene and mounting pre-analysis. 
Lung fibrosis Score  
The fibrosis score of each mouse lung was evaluated from H&E stained lung sections 
by two blinded observers, one independent to the project. Twenty (x40 magnification) non-
overlapping fields of view were assessed per section for the presence of alveolar wall 
thickening: 1 = <25%, 2 = 25-50%, 3 = 50-75%, 4= 75-100% of field affected). Only fields 
composed predominantly of alveoli were quantified.  
Statistical analysis 
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Statistical analysis was performed using Graph Pad Prism software (Version 5.0). For 
the analysis of two groups the unpaired t-test was used, with or without Welch’s correction 
dependent on the variance of data between groups. ANOVA with post-hoc Holm’s Sidak 
multiple comparisons analysis was used for multiple group comparisons. For all tests a p < 
0.05 was considered statistically significant. Data presented as means with SEM.  
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Figure E 1: Sequencing chromatograms of products obtained by RT-PCR of human normal and 
IPF lung RNA extracts. Gel bands were initially digested then analysed by direct sequencing. Using 
VEGF-A Exon 8b reverse primers, products consistent with a) VEGF-A121a b) VEGF-A165a and c) 
VEGF-A189a were sequenced. Using a VEGF-A Exon 7a forward primer, the gel product from IPF 
Patient 3 confirmed the expression of VEGF-A165b (d).   
Figure E 2: Expression of VEGF-A isoforms in normal and IPF lung 
a) Patient demographics of IPF and control groups for BALF data in Figure 1e. Groups were 
statistically comparable (unpaired t-test, IPF group n=15, healthy control group n=13). b) PanVEGF-
A and VEGF-A
165
b immunohistochemical staining: Lower magnification of images shown in Figure 
1f. Intense staining of the alveolar epithelium was observed for both panVEGF-A and VEGF-A
165
b in 
normal and IPF lungs (block arrows). Additional sites of localisation included vessel walls (open 
arrow heads), fibroblasts (FFo indicates the fibrotic focus), lymphocytes and alveolar macrophages 
(AM). Isotype IgG shown as negative control. Scale bar =25µm original magnification x40. 
 
Figure E3A: Expression of VEGFR1, VEGFR2, NP1 and NP2 in the normal and IPF lung 
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VEGF-A receptor and co-receptor immunohistochemical staining: Intense staining of the alveolar 
epithelium was observed for VEGFR1, VEGFR2, NP1 and NP2 (arrows) in both the normal and IPF 
lung. Additional sites of localisation included the vascular endothelium, fibroblasts (FFo indicates the 
fibrotic focus), lymphocytes and alveolar macrophages (AM). Isotype IgG shown as negative control. 
Scale bar=10µm, original magnification x100. 
Figure E 3B: Co-staining of VEGFR1 and VEGFR2 with E-cadherin in a) normal lung and b) 
IPF lung.  
E-Cadherin co-localised with both VEGFR1 and VEGFR2 to the alveolar epithelium in normal lung 
(arrows) In the IPF lung E-Cadherin staining was heterogeneous but again co-localised with VEGFR1 
and VEGFR2 (arrows)(arrowheads) (n=3,  n=1 shown). Original magnification of images x100 (scale 
bar = 10µm). 
Figure E 3C: Expression of VEGFR1, VEGFR2, NP1 and NP2 in NF and FF by qRT-PCR  
a)  NF and FF expressed the key VEGF-A receptors and co-receptor mRNA at comparable levels by 
qRT-PCR (data presented as means with SEM, NF: n=5, FF: n=6, unpaired t- test).  
b) Sequencing chromatograms of products obtained from qRT-PCR of NF and FF cell culture RNA 
extracts. Receptor specific forward primers were used as the template to amplify each target sequence 
of interest. Sequencing confirmed the amplification of VEGFR1, VEGFR2, NP1 and NP2 in NF and 
FF cell extracts (NF n=2, FF n=2 for each product, n=1 shown).   
 
Figure E 4: Densitometric analysis of phosphorylation of MEK and p42/p44 proteins in NF and 
FF in response to VEGF-A165a or VEGF-A165b treatment. Representative western blots shown in 
Figure 3. Increased phosphorylation of MEK and p42/p44 was observed in response to VEGF-A165a 
and VEGF-A165b in both NF and FF compared to SFM (data presented as means with SEM, 
n=3,*p<0.05, **p<0.01, unpaired t-test). 
 
Figure E 5: RT-PCR of VEGF-A isoform expression in NF and FF using Exon2/3 forward 
primer and 8b reverse primer a) Map of exon structures of several of the VEGF-A isoforms with 
predicted isoform length. Arrows indicate panVEGF-A primer positions. b) Agarose gel 
electrophoresis following RT-PCR demonstrating the amplification of at least two isoforms. c) The 
prominent bands produced were excised and sequenced using the 8b reverse primer, confirming the 
amplification of VEGF-A165a and VEGF-A121a.  
 
Figure E 6: RT-PCR of VEGF-A isoform expression in NF and FF using Exon 7a forward 
primer and 8b reverse primer a) Map of exon structures of VEGF-A165a and VEGF-A165b isoforms 
with predicted isoform length. Arrows indicate primer positions. b) RT-PCR of RNA extracted from 
NF (n=5) and FF (n=6) cultures using VEGF-A Exon 7a forward and Exon 8b reverse primers. Two 
bands were observed consistent with the expression of both proximal (VEGF-A165a ~ 195bp) and 
distal splice isoforms (VEGF-A165b ~ 129bp). Plasmids containing VEGF-A165a and VEGF-A165b 
were used as positive controls (alone and mixed in a 1:1 ratio). L indicates 100bp marker.  c) The 
prominent bands produced were excised and sequenced using the 7a forward primer, confirming the 
amplification of VEGF-A165a and VEGF-A165b.  Exons 7 and 8a are highlighted on the sequencing 
chromatogram of the195bp PCR product (Top Band): Codons translated to give the terminal six 
amino acids expected for isoforms of the VEGF-Axxxa family (Cysteine-Aspartic acid-Lysine-Proline-
Arginine-Arginine). Exons 7 and 8b are highlighted on the sequencing chromatogram of the129bp 
PCR product (Bottom band): The highlighted sequence corresponds to Codons translated to give the 
terminal six amino acids specific to the VEGF-Axxxb family of isoforms (Serine-Leucine-Threonine-
Arginine-Lysine-Aspartic acid).  
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Figure E 7: VEGF-A isoform expression in NF and FF.  
Quantitative RT-PCR of NF and FF (n=5) panVEGF-A and VEGF-Axxxb isoform mRNA. No 
significant differences in the mRNA levels of panVEGF-A  or VEGF-Axxxb isoforms were detected 
between NF and FF (unpaired t-test). 
Figure E 8: Cell immunofluorescence of panVEGF-A and VEGF-A165b expression in NF and 
FF. Comparable patterns were observed for NF and FF, with cytoplasmic and perinuclear expression 
of panVEGF-A and cytoplasmic expression of VEGF-A165b. Primary antibody shown in green, 
Phalloidin (F-actin) in red and DAPI (nuclear) in blue, with an overlay image of all three stains. 
Isotype IgG controls were used as negative controls. Images taken at x40 magnification with scale bar 
indicating 25µm.  
Figure E 9: Fibroblast wound healing in response to VEGF-A165a  and VEGF-A165b. VEGF-A165a  
and VEGF-A165b significantly increased the migration of NF at 48 hours (*p<0.05). This effect was 
blocked by the concomitant treatment of VEGF-A165a and VEGF-A165b. Recombinant VEGF-A 
proteins had no significant effect on the migration of FF. Representative images of n=4, Scale bar 
80µm, original magnification x10.).  
Figure E 10: Kidney and Liver sections from GFP-STCL mice : A GFP-reporter mouse 
(ROSA
mT/mG
) was crossed with SPC
+/-
TC
+/-
LoxP
+/- 
mice to determine the tissue specificity of Cre-
recombinase activity following doxycycline induction. These mice possess LoxP sites on either side 
of a membrane-targeted tdTomato (mT) cassette and express red fluorescence in all tissues. In the 
presence of Cre recombinase, the mT cassette is deleted allowing expression of the membrane-
targeted EGFP (mG) cassette located just downstream. Visualisation of kidney and liver sections of 
doxycycline-induced GFP-STCL mice demonstrated an absence of GFP fluorescence at both 12 and 
14 weeks (12 week images shown, images taken at x40 magnification, scale bar 25µm, n=3, n=1 
shown, DAPI (nuclear) counterstain). 
 
Figure E 11: Phenotype of MMTV-VEGF-A165b mice. a) RT-PCR using primers specific for a) 
human panVEGF-A and b) the MMTV-VEGF-A165b transgene comparing transgenic (TG) mice to 
littermate controls (WT). Bands consistent with detectable human VEGF-A165b (i) and the MMTV-
VEGF-A165b transgene (ii) in TG mice. b) H&E stained lung sections of TG mice and WT littermate 
controls. MMTV-VEGF-A165b (TG) mice demonstrated normal parenchymal architecture and 
pulmonary vasculature. Images taken at x10 magnification, scale bar 100µm (a+c) and at x40 
magnification, scale bar 25µm (b+d).  
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Table E 1:Table of primer sequences for human RT-PCR reactions 
Primer name Sequence 
 
  
Human VEGFR1  For : 5’- GAGCTCCCTTCCTTCAGTCA-3’ 
 Rev: 5’-GAAGAAGGAGGCAGAATCTGCAA-3’ 
  
Human VEGFR2  For: 5’-AGAATGGAAGAGGATTCTGG-3’ 
 Rev: 5’-CGGCTCTTTCGCTTACTGTT-3’ 
  
Human NP1  For: 5’-CCCCGGGTACCTTACATCTC-3 
 Rev: 5’-TGCAGTCTCTGTCCTCCAAA-3’ 
  
Human NP2  For: 5’-GAACTGCATGGAACCCATCT-3’ 
 Rev: 5’-CCCTGAGGTTGCAGAAGAAG-3’ 
  
Human PanVEGF (exon2/3) RT-PCR For: 5’-CGA AGT GGT GAA GTT CAT GGAT G-3’ 
  
Human PanVEGF (exon 7a) RT-PCR For: 5’-GTTTGTACAAGATCCGCAGACGT-3’ 
  
Human PanVEGF (exon 7b) qPCR For: 5’–CGTTGCAAGGCGAGGCAGC-3’ 
Human PanVEGF (3’UTR of exon 8b) qPCR+RTPCR Rev: 5’-TTCTGTATCAGTCTTTCCTGGTGA-3’ 
  
Human VEGFxxx only  (exon 7a) qPCR For: 5’-TTGCTCAGAGCGGAGAAAGC-3’ 
                                              (exon 8a) qPCR Rev: 5’-TCACCGCCTCGGCTTGTCACAT-3’ 
  
Human Fibronectin  For: 5’-ACCTAGGATGACTCGTGCTTTGA-3’ 
 Rev: 5’-CAAAGCCTAAGCACTGGCACAACA-3’ 
  
Human β-Actin For: 5’-AGA AGG ATT CCT ATG TGG GCG-3’ 
 Rev: 5’-CAT GTC GTC CCA GTT GGT GAC-3’ 
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Table E 2: Table of primer sequences for murine RT-PCR reactions 
Primer name Sequence 
 
  
Murine Fibronectin For: 5’-AAA CTT GCA TCT GGA GGC AAA CC-3’ 
Rev: 5 ’-AGC TCT GAT CAG CAT GGA CCA CT-3’ 
Murine pro-Collagen-1α For: 5’-GCAACAGTCGCTTCACCTACA-3’ 
Rev: 5’-CAATGTCCAAGGGAGCCACAT-3’ 
Murine panVEGF-A  For: 5’-GGC TAT AAG TTC TTT GCT GAC CTG-3’  
Rev: 5’-AAC TTT TAT GTC CCC CGT TGA-3’ 
Murine HPRT (qPCR) For: 5’-GGC TAT AAG TTC TTT GCT GAC CTG-3’ 
Rev: 5’-AAC TTT TAT GTC CCC CGT TGA-3’ 
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Supplementary Figure 1
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Supplementary Figure 2
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Supplementary Figure 3A
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Supplementary Figure 4
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Exon 8a coding regionNon-coding region Exon 7 coding region
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Band at 545bp: VEGF-A165a, NM_00171626 (variant 4)  
Band at 413bp: VEGF-A121a, NM_001171628.1 (variant 6)  
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Supplementary Figure 5
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Supplementary Figure 6
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a)
Supplementary Figure 7
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Supplementary Figure 8
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a) Normal Fibroblasts
b) Fibrotic fibroblasts
Supplementary Figure 9
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Supplementary Figure 10
Page 58 of 59 AJRCCM Articles in Press. Published on 29-June-2017 as 10.1164/rccm.201603-0568OC 
 Copyright © 2017 by the American Thoracic Society 
L 165a 165b 1:1 WT
TG
2 dH2O
i) Human PanVEGF-A primers (Exon 7a For, 8b Rev)
ii) MMTV-VEGF165 transgene primers
L L1
L 165a 165b 1:1 WT
TG
2 dH2OL L1
Plasmid controls
Plasmid controls
L: Ladder
WT: Wildtype
TG: Transgenic
L: Ladder
WT: Wildtype
TG: Transgenic
WT Littermate CTRL MMTV-VEGF-A165b TG
a)
b)
Supplementary Figure 11
Page 59 of 59  AJRCCM Articles in Press. Published on 29-June-2017 as 10.1164/rccm.201603-0568OC 
 Copyright © 2017 by the American Thoracic Society 
